Hepatitis B surface antigen clearance and appearance of antibodies against hepatitis B surface antigen after treatment with recombinant interleukin 2 in a human immunodeficiency virus-infected patient [1]

Hepatology

Volumn 32, Issue 6, 2000, Pages 1409-1410

  Gianotti, N ^a   Uberti Foppa, C ^a   Boeri, E ^a   Marinelli, M ^a   Tambussi, G ^a   Finazzi, R ^a   Lazzarin, A ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RECOMBINANT INTERLEUKIN 2; SAQUINAVIR; STAVUDINE; VIRUS DNA; ZIDOVUDINE;

CASE REPORT; CLINICAL FEATURE; DRUG EFFECT; DRUG EFFICACY; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRIORITY JOURNAL; SEROCONVERSION; T LYMPHOCYTE; TREATMENT OUTCOME;

HEPATITIS ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HIV INFECTIONS; HUMANS; INTERLEUKIN-2; RECOMBINANT PROTEINS;

EID: 0033658529     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (8)

1. Effects of human recombinant interleukin 2 in patients with chronic hepatitis B: A preliminary report
2. Effect of recombinant interleukin 2 on hepatitis B e antigen positive chronic hepatitis
3. Treatment of chronic hepatitis B with interferon alfa-2b and interleukin-2
4. Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects
5. Double-blind, randomized controlled trial of interleukin-2 treatment of chronic hepatitis
6. Hepatitis B e antigen negative chronic hepatitis B from clinical recognition to pathogenesis and treatment
7. Hepatitis B virus carriers without pre-core mutation in hepatitis B e antigen negative stage show more severe liver damage
8. Induction of IL-1 beta-converting enzyme-independent apoptosis by IL-2 in human T cell lines